Loading
A phase 1/2 trial of Orelabrutinib in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., active and no longer recruiting.
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies is a phase 1/2 interventional study registered as NCT04014205 by Beijing InnoCare Pharma Tech Co., Ltd., with 81 participants enrolled, started 2019-11-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: Orelabrutinib (ICP-022).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InnoCare Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InnoCare Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Orelabrutinib, InnoCare Pharma, Small-molecule kinase inhibitors and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/